Plain-English translation of NCT07349758 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing how your body absorbs and processes a double dose of Descovy, an HIV prevention medication. Researchers want to understand what happens when you take two tablets at once, so they can figure out if people might be able to take this medication less often in the future while still staying protected against HIV.
Current HIV prevention plans usually require taking medication very regularly. This study exists to see whether the medication stays in your body long enough that people might not need to take it as often—which could make it easier for people to use this life-saving prevention tool.
You likely qualify if…
You likely don't qualify if…
You will come to the study clinic and take a double dose (two tablets) of the medication one time. After that, you'll have blood samples drawn at multiple visits over the next 14 days—more frequently right after you take the medication, then less often as time goes on. This helps researchers measure how much medication stays in your blood and tissues at different time points.
AI-generated summary from trial data · Jun 26, 2026 · Not medical advice
United States
Safety & dosing
Sponsor
Johns Hopkins University
Collaborators
National Institute on Drug Abuse (NIDA)
Enrollment target
~24 participants
Started
January 2026
Primary completion
January 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jennifer Hoffmann, CRNP
Johns Hopkins University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.